Sherlock Biosciences is a diagnostics company using CRISPR and synthetic biology platforms to provide at-home molecular testing solutions.
Sherlock Biosciences, founded by Catalio Venture Partner Dr. Jim Collins, has engineered two pioneering technology platforms, called INSPECTR and SHERLOCK, that deliver diagnostic tests with the accuracy of PCR and the convenience and simplicity of antigen tests. By using CRISPR enzymes and synthetic biology, Sherlock’s products can detect DNA and RNA associated with a huge range of diseases. The simplicity of their products means tests can be done at home as well as in a low resource setting, and without the need for specialist knowledge or equipment to process samples or interpret results. Sherlock made history in 2020 when one of its products became the first FDA-authorized use of CRISPR technology; the company is positioned to transform the quality and patient experience of at-home diagnostics.
Sherlock Biosciences, founded by Catalio Venture Partner Dr. Jim Collins, has engineered two pioneering technology platforms, called INSPECTR and SHERLOCK, that deliver diagnostic tests with the accuracy of PCR and the convenience and simplicity of antigen tests. By using CRISPR enzymes and synthetic biology, Sherlock’s products can detect DNA and RNA associated with a huge range of diseases. The simplicity of their products means tests can be done at home as well as in a low resource setting, and without the need for specialist knowledge or equipment to process samples or interpret results. Sherlock made history in 2020 when one of its products became the first FDA-authorized use of CRISPR technology; the company is positioned to transform the quality and patient experience of at-home diagnostics.
Location: United States, Massachusetts, Boston
Total raised: $146M
Investors 1
| Date | Name | Website |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.03.2022 | Series B | $80M | - |
| 23.04.2019 | Series A | $31M | - |
| 21.03.2019 | - | $35M | - |
Mentions in press and media 19
| Date | Title | Description |
| 09.09.2025 | Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say | Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say By Svea Herbst-BaylissSeptember 9, 202510:19 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Item 1 ... |
| 09.09.2025 | Exclusive-Altai Capital lays groundwork for board fight at OraSure Technologies, sources say | Previous A man walks past an advertisement for the OraQuick HIV self-testing kit, manufactured by Orasure Technologies, in the Mathare slum, in Nairobi, Kenya, October 30, 2020. Picture taken October 30, 2020. REUTERS/Baz Ratner/File Photo ... |
| 13.07.2023 | Diagnostic Testing Landscape Paves the Way for Consumer Centric Approach to Disease Detection | The diagnostics sector has benefited from a few trends in the past five years that not only have the potential to transform how we screen for cancer but also detect chronic conditions— such as cardiovascular disease— earlier, which could le... |
| 10.03.2022 | Sherlock Biosciences Scores $80M in Series B | BOSTON, MA, Sherlock Biosciences, a company engineering biology, has raised $80 million in a Series B financing led by Novalis LifeSciences. >> Click here for more funding data on Sherlock Biosciences >> To export Sherlock B... |
| 08.03.2022 | Sherlock Biosciences raises $80M Series B for at-home diagnostics | Sherlock Biosciences announced today that it raised $80 million in a Series B financing round to support its next-generation diagnostics. Novalis LifeSciences led the round, which included new investors Illumina Ventures, Albany Capital and... |
| 08.03.2022 | Sherlock Biosciences Raises $80 Million in Series B Financing to Democratize At-Home Diagnostic Testing | - |
| 08.03.2022 | Sherlock Biosciences Raises $80M in Series B Funding | Sherlock Biosciences, a Boston, MA-based biology diagnostics company, raised $80M in Series B funding. The round was led by Novalis LifeSciences with participation from Illumina Ventures, Albany Capital and Catalio Capital Management. Paul ... |
| 03.03.2021 | CRISPR rivals put patents aside to help in fight against Covid-19 | In early January 2020, Feng Zhang, a gene-editing researcher at the Broad Institute of MIT and Harvard, started getting emails written in Chinese about a newly identified coronavirus that was spreading in China. Some were from academics he ... |
| 10.06.2020 | How CRISPR research in Delaware can fight both COVID-19 and inequity in health outcomes | In March, Dr. Eric Kmiec, director of ChristianaCare’s Gene Editing Institute (GEI), and Dr. Jonathan Marron, oncologist at Boston Children’s Hospital and instructor at Harvard Medical School, published the op-ed “Potential Inequities in Ne... |
| 08.05.2020 | FDA Approves CRISPR-Based Coronavirus Test | Public health officials universally agree that the world needs much more coronavirus testing before we can safely ease current lock-down restrictions. Even at the low end, experts say we’ll need to do hundreds of thousands more daily tests,... |
Show more